$2.59 Billion is the total value of DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s 134 reported holdings in Q3 2015. The portfolio turnover from Q2 2015 to Q3 2015 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ALLSCRIPTS HEALTHCARE SOLUTNnote 1.250% 7/0 | $99,819,000 | -3.6% | 100,750,000 | 0.0% | 3.86% | +11.9% | ||
| FLML | FLAMEL TECHNOLOGIES SAsponsored adr | $66,428,000 | -23.0% | 4,072,809 | 0.0% | 2.57% | -10.6% | |
| VNDA | VANDA PHARMACEUTICALS INC | $53,965,000 | -11.1% | 4,784,157 | 0.0% | 2.09% | +3.2% | |
| NVLS | NIVALIS THERAPEUTICS INC | $48,409,000 | -14.4% | 3,732,412 | 0.0% | 1.87% | -0.6% | |
| ARRAY BIOPHARMA INCnote 3.000% 6/0 | $43,864,000 | -23.0% | 45,000,000 | 0.0% | 1.70% | -10.5% | ||
| EHTH | EHEALTH INC | $41,819,000 | +0.9% | 3,264,588 | 0.0% | 1.62% | +17.2% | |
| ENDOLOGIX INCnote 2.250%12/1 | $36,877,000 | -7.3% | 40,941,000 | 0.0% | 1.43% | +7.7% | ||
| HWAY | HEALTHWAYS INC | $27,411,000 | -7.2% | 2,465,042 | 0.0% | 1.06% | +7.7% | |
| FLUIDIGM CORP DELnote 2.750% 2/0 | $25,235,000 | -18.5% | 35,000,000 | 0.0% | 0.98% | -5.3% | ||
| WEBMD HEALTH CORPnote 1.500%12/0 | $23,640,000 | -4.0% | 23,000,000 | 0.0% | 0.91% | +11.3% | ||
| GI | ENDOCHOICE HLDGS INC | $20,422,000 | -30.5% | 1,797,709 | 0.0% | 0.79% | -19.3% | |
| ANTM | ANTHEM INC | $19,713,000 | -14.7% | 140,806 | 0.0% | 0.76% | -0.9% | |
| PRTO | PROTEON THERAPEUTICS INC | $17,601,000 | -22.1% | 1,265,343 | 0.0% | 0.68% | -9.6% | |
| PTLA | PORTOLA PHARMACEUTICALS INC | $14,058,000 | -6.4% | 329,837 | 0.0% | 0.54% | +8.6% | |
| ALIM | ALIMERA SCIENCES INC | $9,769,000 | -52.1% | 4,420,580 | 0.0% | 0.38% | -44.3% | |
| TNXP | TONIX PHARMACEUTICALS HLDG C | $6,959,000 | -41.0% | 1,315,551 | 0.0% | 0.27% | -31.6% | |
| FOMX | FOAMIX PHARMACEUTICALS LTD | $6,956,000 | -28.5% | 948,934 | 0.0% | 0.27% | -17.0% | |
| RIGL | RIGEL PHARMACEUTICALS INC | $5,923,000 | -23.0% | 2,397,855 | 0.0% | 0.23% | -10.5% | |
| SCYX | SCYNEXIS INC | $5,043,000 | -17.2% | 692,781 | 0.0% | 0.20% | -3.9% | |
| TCON | TRACON PHARMACEUTICALS INC | $4,738,000 | -13.8% | 485,000 | 0.0% | 0.18% | 0.0% | |
| LIFE | ATYR PHARMA INC | $4,735,000 | -44.6% | 461,530 | 0.0% | 0.18% | -35.8% | |
| ALDX | ALDEYRA THERAPEUTICS INC | $4,026,000 | -24.9% | 690,538 | 0.0% | 0.16% | -12.8% | |
| CASM | CAS MED SYS INC | $4,000,000 | -2.3% | 3,200,000 | 0.0% | 0.16% | +14.0% | |
| PRQR | PROQR THRAPEUTICS N V | $3,051,000 | -12.6% | 209,398 | 0.0% | 0.12% | +1.7% | |
| CDTX | CIDARA THERAPEUTICS INC | $3,022,000 | -9.3% | 237,583 | 0.0% | 0.12% | +5.4% | |
| BITI | BIOTIE THERAPIES OYJsponsored adr | $2,874,000 | -34.5% | 219,558 | 0.0% | 0.11% | -24.0% | |
| TRILLIUM THERAPEUTICS INC | $2,245,000 | -40.3% | 172,307 | 0.0% | 0.09% | -30.4% | ||
| VCYT | VERACYTE INC | $1,797,000 | -57.9% | 383,256 | 0.0% | 0.07% | -50.7% | |
| ATEC | ALPHATEC HOLDINGS INC | $1,644,000 | -76.1% | 4,982,738 | 0.0% | 0.06% | -72.1% | |
| PTN | PALATIN TECHNOLOGIES INC | $1,620,000 | -9.0% | 2,000,000 | 0.0% | 0.06% | +6.8% | |
| KIN | KINDRED BIOSCIENCES INC | $1,452,000 | -23.7% | 279,204 | 0.0% | 0.06% | -11.1% | |
| BVX | BOVIE MEDICAL CORP | $1,342,000 | -30.1% | 688,229 | 0.0% | 0.05% | -18.8% | |
| NVTA | INVITAE CORP | $1,203,000 | -51.5% | 166,666 | 0.0% | 0.05% | -43.4% | |
| CDNA | CAREDX INC | $955,000 | -35.9% | 229,000 | 0.0% | 0.04% | -26.0% | |
| CORSICANTO LTDnote 3.500% 1/1 | $917,000 | -15.4% | 1,000,000 | 0.0% | 0.04% | -2.8% | ||
| POZN | POZEN INC | $260,000 | -43.5% | 44,583 | 0.0% | 0.01% | -33.3% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-11-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AERIE PHARMACEUTICALS INC | 36 | Q3 2022 | 3.6% |
| CENTENE CORP DEL | 30 | Q3 2023 | 3.0% |
| BIOCRYST PHARMACEUTICALS INC | 29 | Q3 2023 | 2.2% |
| MOLINA HEALTHCARE INC | 26 | Q3 2022 | 1.7% |
| EHEALTH INC | 25 | Q3 2020 | 2.0% |
| INTERCEPT PHARMACEUTICALS IN | 24 | Q1 2023 | 2.2% |
| MYLAN NV | 23 | Q3 2020 | 6.2% |
| PORTOLA PHARMACEUTICALS INC | 23 | Q1 2019 | 6.0% |
| BROOKDALE SR LIVING INC | 23 | Q3 2023 | 2.2% |
| ALIMERA SCIENCES INC | 23 | Q3 2019 | 0.8% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| DA32 Life Science Tech Acquisition Corp. | August 01, 2023 | 5,145,000 | 91.1% |
| CareMax, Inc. | March 13, 2023 | 18,691,423 | 16.4% |
| CareMax, Inc. | June 02, 2022 | 18,691,423 | 20.7% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 3 | 2024-03-19 |
| 4 | 2024-03-19 |
| 4 | 2024-03-12 |
| 3 | 2024-03-08 |
| 4 | 2024-02-16 |
| 13F-HR | 2024-02-14 |
| 4 | 2024-02-08 |
| 3 | 2024-02-01 |
| 4 | 2023-11-21 |
| 13F-HR | 2023-11-14 |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.